Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 8711 publications.

Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283

Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presentation to be given at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang Y-K. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Sauchelli Toran S, Whalley D, Orfanos P, Kohli R, Balp MM. Clinical relevance of disease activity scores from the patient perspective in chronic spontaneous urticaria. Poster to be given at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain.

Ling C, Hawe E, Stevenson A, Low EW. Giving voice to rare diseases during joint clinical assessment (JCA). Presentation to be given at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain.

van Til J, Poulos C, Thomas C. Using health preference methods for value clarification in patient decision support: current use and future developments. Presentation to be given at the ISPOR Europe 2024; November 19, 2024. Barcelona, Spain.

Msihid J, Joulain F, Hawe E, Burgess B, Thomas RB, Tilton ST. Assessing the relationship between EQ-5D-3L index scores and disease-specific patient-reported outcome measures in eosinophilic oesophagitis. Poster to be given at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spaine.

Desai A, Dong OM, Gautier S, Johnson T, Wong A, Osman AMY, Harvey J, Tran TH, Holladay Ford DM, Kerr KW, Aggarwal A, Mauskopf J. A systematic review of health economic evaluations of oral nutritional supplements as a single-component or multi-component intervention in older adults with or at risk of malnutrition. Poster to be given at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spain.

Whalley D, Balp MM, Yarr S, Korver D, Sauchelli Toran S, Kohli R, Orfanos P. Psychometric evaluation of the urticaria activity score in chronic spontaneous urticaria. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Marcano Belisario J, Lunan M, Hawe E, Thurairajah S. Machine learning and artificial intelligence for supporting systematic reviews: a systematic review of recent methodological developments and recommendations for implementation. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Sullivan SD. Economic evaluation of dupilumab versus standard of care for the treatment of adult patients with moderate-to-severe prurigo nodularis in the United States. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Johannesen K, Herring WL, Chopra R, Elpers B, Dong O. Using patient-level simulation to estimate long-term survival in idiopathic pulmonary fibrosis. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Burgess B, Leng X, Brizan J, Hawe E. Meta-analysis of pre-post studies: why standardised mean difference should be avoided. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Clemmet T, Campbell K, Basarir H. Key features of economic models used in submissions to NICE in dermatology indications. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the economic burden of hemophilia A and B. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the humanistic burden of hemophilia A and B. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Ronquest N, Zhang Y, Paret K, Armstrong S, Mostovoy L, Berggren R. Identifying the value drivers in obesity treatment: a targeted review of weight loss effects on health economic outcomes. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ. Advanced patient-reported outcomes. Presentation to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. Previously presented at the ISPOR 2024.

Clemmet T, Basarir H, Buompensiere MI, Chrastecka N, de Portu S, Dias RP, Dunne JL, del Pozo CH, Mader JK, Narendran P, Nicholls C, Alsaleh AJO, Piemonti L, Vercauteren J, Mahieu A. Economic evaluations of screening in pre-symptomatic type 1 diabetes (T1D): a systematic literature review. Poster presented at the Immunology of Diabetes (IDS) Congress 2024; November 4, 2024. Bruges, Belgium.

Ni L, Harris M, Cotterill G, Hoog M, Basarir H, Deger K, van Hest N, Johansson E. Comparison of cost-effectiveness model outcomes using two individual-level simulation models in obesity. Presented at the ISPOR Europe 2024; November 2024. Barcelona, Spain.

Sauchelli Toran S, Whalley D, Balp MM, Kohli R, Orfanos P. Content validity of the angioedema activity score from the perspective of adults with chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2024; November 2024. Barcelona, Spain.

Loria-Rebolledo LE, van Woerden HC, Bryers H, Erdem S, Watson V. Preferences of recent mums in remote and rural areas for type of intrapartum care: a discrete choice experiment. Patient. 2024 Nov;17(6):663-72. doi: 10.1007/s40271-024-00704-8.

Gelsey FT, Schapiro D, Kosa K, Vass CM, Perez-Nieves M, Pierce A, Poon JL, DiBenedetti D, Mansfield C. Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin. Diabetes Ther. 2024 Nov;15(11):2367-79. doi: 10.1007/s13300-024-01652-0

Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):223-35. doi: 10.1007/s10549-024-07469-6

Yousif Z, Nangia A, Abeysinghe S, Jiang J, Sanchirico M, Fan T. Comparative efficacy of biologics for the induction of clinical remission and response in biologic-naïve patients with moderate-to-severe crohn's disease: outcomes from frequentist and bayesian network meta-analyses. Poster presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024; October 29, 2024. Philadelphia, PA.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Comparing the mortality risk of patients on FDA-approved treatment for Parkinson's disease psychosis, pimavanserin, vs other antipsychotics. Poster presented at the 37th Annual Psych Congress; October 29, 2024. Boston, MA. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Dine J, Lee J, Shewale A, Stokes J, Basnyat B, Brown M, Greenblatt A, Shirneshan E. Understanding the early Alzheimer's disease experience: perspectives from patients and caregivers. Poster presented at the 17th Clinical Trials on Alzheimer's Disease (CTAD) 2024; October 29, 2024. Madrid, Spain.

Chapman KR, Guyot P, Ledanois O, Soliman M, Wang Z, Xu Y, Nangia A, Cheng W-H. Efficacy of dupilumab versus tezepelumab in asthma patients: matching-adjusted indirect comparison of long-term extension trials. Poster presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting; October 25, 2024. Boston, MA.

Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Oct 24. doi: 10.1007/s40121-024-01064-4

Dave RH, Crayton H, Miravalle A, Tai MH, Wyse K, Houghton K, Hitchens A, Berkovich R. COVID-19 vaccination response in patients with multiple sclerosis treated with ofatumumab in the United States: a medical record review. Neurol Ther. 2024 Oct 23. doi: 10.1007/s40120-024-00671-0

Khodabakhsh S, Hoffmann C, Sauchelli S, Shi G, Mitchell A. A novel approach to peer support for academic researchers. Occup Med (Lond). 2024 Oct 19. doi: 10.1093/occmed/kqae091

Broughton EI, Bektas M, Colosia A, Fernandez M, Kuper K, Al-Taie A, Kotb REM. Assessing the global economic burden of complicated urinary tract infections. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, California.

La E, Sweeney C, Singer D, Davenport E, Calhoun S, Harmelink A. Factors associated with healthcare professionals' RSV older adult vaccination knowledge and practices during the first season of vaccine availability in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.

Carrico J, Talbird SE, Eiden A, Carias C, Huang M, Lang JC, Marshall GS, Bencina G. Direct impact of pediatric immunization on reduction in antibiotic prescribing in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.

Rider NL, Zichlin ML, Schick B, Berstein M, Fladhammer D, Schwab P, Gladiator A. Evaluating treatment experience during initiation of subcutaneous immunoglobulin replacement therapy at home using a custom interactive voice assistant. Poster presented at the 21st Biennial Meeting of European Society for Immunodeficiencies (ESID); October 16, 2024. Marseille, France.

DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Oct 15;S0149-291. doi: 10.1016/j.clinthera.2024.09.010

Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438

Bratlee-Whitaker E, Hill NL, Mogle J, Bhargava S, DeMuro Romano C. Older adults' dementia worry, self-reported cognition, and control beliefs about cognitive aging: a mixed methods study. Presented at the 31st Annual Conference of the International Society for Quality of Life Research (ISOQOL); October 15, 2024. Cologne, Germany. [abstract] Qual Life Res. 2024 Oct 14; 33(Suppl 1).

Grace M, Wang K, Graham CN. Budget impact of injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity on a third-party US payer. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Sauchelli S, Levy C, Gnanasakthy A, Doward L, Fitzgerald K. Inclusion of patient-reported outcome endpoints in the summary of product characteristics for non-oncology drugs approved by the European Medicines Agency (2018-2022). Poster presented at the ISOQOL 31st Annual Conference; October 13, 2024. Cologne, Germany.